The results of these analyses for safety profiles have provided valuable information for the development of therapeutic strategies for ALK inhibitor naïve ALK-p advanced NSCLC, suggesting that particularly high and adequate safety considerations may be required when lorlatinib is administered. This evidence concerns the gene ALK and non-small cell lung carcinoma.